AMPHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Amphastar Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$26.14+0.27 (+1.04%)
Close on Oct 19, 2026
- Market cap
- $1.16B
- P/E (TTM)
- 15.4
- Dividend yield
- –
Share price
+$2.36 (+9.92%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Amphastar Pharmaceuticals, Inc. grew revenue 1.0% to $730.02M over the twelve months to Jun 30, 2026. Operating income fell 37.1% to $114.29M, moving the operating margin from 25.1% to 15.7%. Free cash flow was $152.89M, up 36.3% from a year earlier.
Revenue
$730.02M
+1.0% vs. a year earlier
Operating income
$114.29M
-37.1% vs. a year earlier
Free cash flow
$152.89M
+36.3% vs. a year earlier
EPS, diluted
$1.70
-36.3% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $1.16B
- P/E ratio
- 15.4
- Price to sales
- 1.58
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- 13.23%
Fundamentals
- Revenue
- $730.02M
- Net income
- $78.55M
- EPS, diluted
- $1.70
- Free cash flow
- $152.89M
- Diluted shares
- 44M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$730.02M+1.0% YoY
Gross profit
$348.11M-3.4% YoY
Operating income
$114.29M-37.1% YoY
Net income
$78.55M-41.7% YoY
EPS, diluted
$1.70-36.3% YoY
Free cash flow
$152.89M+36.3% YoY
Reported periodTrailing twelve months